Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 6, 1997, Pages 1719-1724

  Collet, J P ^g   Shapiro, S ^j   Ernst, P ^h   Renzi, P ^d   Ducruet, T ^j   Robinson, A ^j   Gauthier, G ^a   Beaupre A ^a   Gregoire P ^b   Jacquemin, P ^b   Plante, F ^b   Lachance, Y ^b   Provost, G ^b   Hernandez, P ^c   Jean Francois R ^c   Charbonneau, ^c   Inhaber, N ^c   Braidy, J ^d   Jeanneret, A ^e   Bolduc, P ^e,l   Leblanc, P P ^e,l   Olivenstein, R ^f   Mannix, S ^f   Chrysler, B ^f   Wolkove, N ^g   Kreisman, H ^g   Frank, ^g   Fox, J ^g   Colman, N ^h   Gruber, J ^h   Zidulka, ^h   Gursahaney, A ⁱ   Matouk, ⁱ   Eidelman, D ⁱ   Julien, M ^j   Malo, J ^j   Dandurand, R ^k   Skamene, E ^j   Suissa, S ^j   Choi, S ^j   Martin, J ^j   Dankoff, G ^j   Enjalbert, M ^j   Lauener, P A ^j   more..

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Centre Hospitalier de Verdun

^c NOTRE DAME HOSPITAL   (Canada)

^d Hôpital Saint Luc

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MONTREAL GENERAL HOSPITAL   (Canada)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^j Clinque Lakeshore ^*

^k Hôpital Le Gardeur

^l Hop St Luc Clinique Rive Sud

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LYSATE; IMMUNOSTIMULATING AGENT;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 6844250986     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.6.9612096     Document Type: Article

References (34)

1. Davies, S. F., and R. H. Ingram. 1993. Chronic obstructive diseases of the lung. In E. Rubenstein and D. D. Federman, editors. Scientific American Medicine. Scientific American, Inc., New York.
2. Cherniak, N. S. 1991. Chronic Obstructive Pulmonary Disease. W. B. Saunders, Philadelphia.
3. Guyatt, G. H., M. Townsend, L. B. Berman, and S. O. Pugsley. 1987. Quality of life in patients with chronic airflow limitations. Br. J. Dis. Chest 81:45-54.
4. Chow, A. W., C. R. Hall, J. O. Klein, E. S. Hershfield, G. K. M. Harding, and N. A. Nelson. 1992. General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin. Infect. Dis. 15(Suppl. 1):S62-S88.
5. National Center for Health Statistics. 1986. Current estimates from the National Health Interview Survey, United States. Vital and Health Statistics, Series 10, no. 164. Hyattsville, MD. DHHS (PHS) 897-1592.
6. Higgins, M. W., and T. Thom. 1989. Incidence, prevalence and mortality: intra- and intercountry differences. In M. J. Hensley and N. A. Saunders, editors. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. Marcel Dekker, New York. 23-29.
7. Feinleib, M., H. M. Rosenberg, and J. G. Collins, et al. 1989. Trends in COPD morbidity and mortality in the United States. Am. Rev. Respir. Dis. 140(Suppl.):S9-S18.
8. Higgins, M. W. 1989. Chronic airways disease in the United States: trends and determinants. Chest 96(Suppl.):328S-334S.
9. Higgins, M. 1984. Epidemiology of COPD. Chest 85(Suppl.):35-85.
10. American Thoracic Society. 1986. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma (ATS statement). Am. Rev. Respir. Dis. 136:225-244.
11. Anthoninsen, N. R., J. Manfreda, C. P. W. Warren, R. B. Kammer, R. D. Meyer, and J. S. Remington. 1987. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann. Intern. Med. 106:196-204.
12. Mauël, J., T. Van Pham, B. Kreis, and J. Bauer. 1989. Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. Int. J. Immunopharmacol. 11:637-645.
13. Keller, R. 1984. Multicentre double blind study of the Broncho-Vaxom in chronic bronchitis. Prax. Klin. Pneumol. 38:225-228.
14. Ahrens, J. 1983. A double blind multicentre trial with Broncho-Vaxom in adults. Atemwegs Lungenkrankeheiten 9:424-427.
15. Geiser, G. 1983. Prevention of respiratory diseases in a large industrial enterprise: double blind study of Broncho-Vaxom. Acta Therap. 9: 289-303.
16. Messerli, C., F. Michetti, P. Sauser-Hall, C. Stäubli, M. Taddei, S. Weiss, J. C. Farine, and Th. Fux. 1981. Effect of a bacterial lysate (Broncho-Vaxom) in the treatment of chronic bronchitis: a multicentre double blind clinical trial. Rev. Med. Suisse Romande 101:143-146.
17. Xinogalos, S., D. Duratsos, and D. Varonos. 1993. Clinical effectiveness of Broncho-Vaxom in patients with chronic obstructive pulmonary disease. Int. J. Immunother. 9:135-142.
18. Maestroni, G. J. M., and G. A. Lose. 1984. Clinical and immunibiological effects of an orally administered bacterial extract. Int. J. Immunopharmacol. 6:111-117.
19. Paupe, J. 1991. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration 58:150-154.
20. Collet, J. P., T. Ducruet, M. S. Kramer, J. Haggerty, D. Floret, J. J. Chomel, F. Durr and the Epicrèche Research Group. 1993. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. Pediatr. Infect. Dis. J. 12:648-652.
21. Derenne, J. P., and B. Delclaux. 1992. Clinical experience with OM-85 BV in upper and lower respiratory tract infections. Respiration 59 (Suppl. 3):29-31.
22. Ware, J. 1994. SF-36 Physical and Mental Health Summary Scales: A User's Manual. The Health Institute, New England Medical Center.
23. McGavin, C. R., M. Artvinli, H. Naoe, and G. J. R. McHardy. 1978. Dyspnoea, disability and distance walked: comparison of estimates of exercise performance in respiratory disease. B.M.J. 2:241-243.
24. 2 on Guinea Pigs Alveolar Macrophages after Treatment with Broncho-Vaxom. International Symposium, Bad Lippspringe, July 26-29, 1989. Allergologie 12(7):300.
25. Bottex, C., B, Cristau, J. L. Corazza, B. Mougin, and R. Fontanges. 1988. Effects of two bacterial extracts, OM-89 and Broncho-Vaxom, on IL-1 release and metabolic activity of a murine macrophage cell-line. Int. J. Immunother. IV:203-212.
26. Wybran, J., M. Libin, and L. Schandene. 1989. Activation of natural killer cells and cytokine production in man by bacterial extracts. Immunopharm. Immunotox. 11:17-32.
27. Fontanges, R., C. Bottex, B. Cristau, and M. F. Burckhart. 1990. Influence of a bacterial extract on antigen presentation and protection against experimental infections. 168(Suppl.):716-719.
28. Duchow, J., A. Marchant, J. P. Delville, L. Schandene, and M. Goldman. 1992. Upregulation of adhesion molecules induced by Broncho-Vaxom on phagocytic cells. Int. J. Immunopharmacol. 14:761-766.
29. Bosch, A., F. Lucena, R. Parès, and J. Jofre. 1981. Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by a bacterial derivative (Broncho-Vaxom). Immunology 160: 9-10.
30. Fontanges, R., J. Mathieu, and P. Gerasimo. 1989. Effect of Broncho-Vaxom (BV) on experimental pleuresy model in rate and production of LTB4 and PAF. International Symposium on Mucosal Immunity of the Respiratory Tract, Bad Lippspringe, July 26-29, 1989. Allergologie 12(7):300.
31. Georgopoulos, A. 1991. Influence of Broncho-Vaxom in Experimental Infection Models in Animals. First Annual Congress, European Respiratory Society, September 1991, Bruxelles.
32. Puigdollers, J. M., R. G. Serna, I. Hernandez del Rey, M. T. Baruffet, and J. J. Toroella. 1980. Immunoglobulin production in man stimulated by an orally administered bacterial lysate. Respiration 40:142-149.
33. Emmerich, B., H. P. Emslander, K. Pachmann, M. Hallek, D. Milatovic, and R. Busch. 1990. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom, on T-lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 57:90-99.
34. Lusuardi, M., A. Capelli, S. Carli, E. L. Spada, A. Spinazzi, and C. F. Donner. Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest (In press)